Most people with diabetes who use insulin qualify for continuous glucose monitoring (CGM) coverage through Medicare and most private insurers. But insulin use isn’t the only path. If you have a history of dangerous low blood sugar episodes, you may also qualify, even without insulin. The specific criteria depend on your insurance type, your diabetes management plan, and how your doctor documents your need.
Medicare Coverage Criteria
Medicare Part B covers CGMs for all diabetes patients who meet at least one of these conditions: you are treated with insulin, or you have a history of problematic hypoglycemia. Your doctor must prescribe the CGM in line with its FDA-approved use, and you need an in-person or telehealth visit within six months before ordering the device so your provider can evaluate your diabetes control and confirm you meet the criteria.
This is broader than it used to be. Before April 2023, Medicare primarily covered CGMs for people on intensive insulin therapy, meaning multiple daily injections or an insulin pump. The updated policy expanded access to include people on basal insulin alone, opening coverage to roughly 1.5 million additional Medicare beneficiaries who use once- or twice-daily long-acting insulin. If you take any form of insulin and have Medicare, you likely qualify.
For the “problematic hypoglycemia” pathway, you don’t need to be on insulin at all. This applies if you experience episodes where your blood sugar drops below 54 mg/dL or if you have severe episodes that require someone else’s help to treat. These are classified as level 2 and level 3 hypoglycemia, respectively. They can occur in people taking certain oral diabetes medications like sulfonylureas, not just insulin.
Once you have a CGM, keeping coverage requires a follow-up visit with your provider every six months. At that appointment, your doctor documents that you’re actively using the device and following your diabetes treatment plan. Missing these visits is one of the most common reasons for coverage lapses.
Private Insurance Requirements
Private insurers generally set tighter eligibility rules than Medicare, though this varies significantly by company. Two of the largest insurers, Anthem and Aetna, have historically required that you have type 1 diabetes and document at least four fingerstick blood glucose tests per day before approving a CGM. The logic behind the fingerstick requirement is to prove you’re actively engaged in glucose management, but it has been widely criticized as an unnecessary barrier that penalizes people who would benefit most from switching away from fingersticks.
UnitedHealth has loosened this somewhat, requiring instead that you demonstrate adherence to a physician-ordered treatment plan without specifying a minimum number of daily fingersticks. Coverage details for Humana, Cigna, and Kaiser Permanente are harder to pin down, as their criteria aren’t always published publicly. Your best starting point is calling the number on your insurance card and asking specifically about CGM medical necessity criteria for your diagnosis.
If your insurer denies coverage initially, your doctor can often submit a prior authorization or appeal that documents why a CGM is medically necessary for you. This is especially effective if you have documented episodes of severe low blood sugar, wide swings in glucose that fingersticks miss, or an A1C that remains above target despite active management.
Type 2 Diabetes Without Insulin
This is where qualification gets more nuanced. If you have type 2 diabetes and don’t take insulin or medications that cause low blood sugar, insurance coverage for a CGM is still limited in many cases. However, clinical guidelines are moving in your favor.
The 2025 American Diabetes Association Standards of Care recommend considering CGM for adults with type 2 diabetes on non-insulin therapies who are working toward personalized blood sugar goals. The recommendation also supports periodic CGM use, at least every three months with provider review, as a tool to guide medication or lifestyle changes. For people at higher risk of hypoglycemia, even without insulin, continuous daily CGM access is suggested by both the ADA and the American Association of Clinical Endocrinologists.
In practice, this means your doctor can make a strong clinical case for CGM if you have suboptimal blood sugar control, if you’re in a structured lifestyle modification program where real-time glucose data would help you change eating and exercise habits, or if you’ve had diabetes-related emergency visits. Whether your insurer agrees to cover it is a separate question, but having guideline support strengthens any appeal.
Pregnancy and Gestational Diabetes
If you have type 1 diabetes and are pregnant or planning pregnancy, CGM is recommended as part of your management. The evidence is strongest here: CGM helps achieve tighter blood sugar targets during pregnancy, which reduces risks for both parent and baby.
For gestational diabetes or type 2 diabetes during pregnancy, the picture is less clear-cut. The ADA notes insufficient data to recommend CGM for all people with gestational diabetes. One randomized trial found no significant difference in adverse birth outcomes between CGM users and those using standard fingerstick monitoring, while another found that CGM improved time spent in the target glucose range. Because optimal CGM targets for gestational diabetes haven’t been formally defined yet, the ADA recommends individualizing the decision based on your treatment plan, preferences, and circumstances. Coverage from insurers for gestational diabetes CGM use is inconsistent.
Children and Adolescents
Age restrictions depend on the specific CGM device. Newer generations of popular sensors have received FDA clearance for younger age groups, but earlier models carried an 18-and-older restriction. When your child’s provider prescribes a CGM, the device chosen must be FDA-approved for your child’s age. Most pediatric endocrinologists are familiar with which systems are cleared for which ages and will prescribe accordingly. Insurance coverage for children with type 1 diabetes is generally straightforward, as the medical necessity is well established.
Prediabetes and Other Metabolic Conditions
If you don’t have a diabetes diagnosis, getting insurance to cover a CGM is extremely unlikely. CGMs are FDA-indicated for diabetes management, and insurers follow those indications closely. Conditions like prediabetes and polycystic ovary syndrome (PCOS) involve insulin resistance and glucose variability, and early research has shown that CGM can detect meaningful glucose pattern differences in people with PCOS. But feasibility studies are not the same as treatment guidelines, and no major insurer currently covers CGM for these conditions.
You can purchase a CGM out of pocket without a prescription for some over-the-counter models, or with a prescription for others. Costs typically run $75 to $150 per month depending on the system. Some people with prediabetes use CGMs this way for short periods to understand how specific foods and habits affect their blood sugar, then stop once they’ve gathered enough personal data to make changes.
What Your Doctor Needs to Document
Regardless of your insurance type, your provider plays a central role in whether your CGM gets approved. For Medicare, the treating practitioner must document that you’ve been evaluated for diabetes control, that you (or a caregiver) can use the device, and that the prescription matches the CGM’s FDA indications. No specialist referral is required. Your primary care physician, endocrinologist, or any qualified provider managing your diabetes can prescribe a CGM.
For private insurance prior authorizations, the strongest documentation includes your current A1C, a record of hypoglycemic episodes (dates, severity, and whether assistance was needed), your current medication regimen, and a clear statement of why fingerstick monitoring alone is insufficient. If you’ve been tracking your blood sugar with fingersticks, bring that log to your appointment. The more concrete evidence your doctor can include, the less likely your claim is to be denied or delayed.